Characterization of Recurrent Mutations in Patient with a Richter Syndrome By Targeted Next Generation Sequencing
Authors: Stamatopoulos Basile , Antoniou Pavlos , Vavoulis Dimitris , Eyre Toby A. , Clifford Ruth , Cabes Maité , Dreau Hélène , Schuh Anna 
Published: October 2019

Background:Up to 10% of patients with chronic lymphocytic leukemia (CLL) undergo a high-grade transformation called Richter Syndrome (RS), most commonly of the diffuse large B cell lymphoma type. In ~80% of cases, the lymphoma originates from the CLL clone and is associated with a median survival inferior to 1 year after diagnosis. Prognosis following standard immunochemotherapy remains very poor and new therapeutic targets for RS are urgently needed.

Methods:Only samples from patients with newly diagnosed RS recruited into the UK CHOP-OR (CHOP in combination with Ofatumumab, EudraCT number 2009-016459-23) were included (Eyre et al, Br J Haematol. 2016). DNA was extracted from 35 peripheral blood mononuclear cells (leukemic phase) and 21 FFPE-lymph node slides (Richter phase). For 15 patients, paired CLL and RS phase were available. A TruSeq Custom Amplicon panel (TSCA, Illumina) was designed targeting 28 recurrently mutated genes in CLL based on recent publications. Average sequencing depth was 2311x. Single nucleotide variant (SNV) were filtered with a variant allele frequency (VAF) >10%, with a depth >20, with an altered variant read >6 and by excluding synonymous mutation and mutation with a frequency >5% in the general population. Mutation frequencies were compared to those of Landau et al based on a CLL population of 538 patients.

Results: Pathogenic mutations were identified in 28/30 CLL phase (93%) and 18/18 (100%) of RS phase. In the majority of paired cases (80%), mutations identified in the CLL phase were confirmed in the RS phase. Additional mutations were acquired in the RS phase compared to the CLL phase (277 versus 82) with a median of 5.5 mutations/RS phase versus 3 mutations/CLL phase (P=0.0003). When compared to the frequency in a general CLL population, we observed a significant increase of mutations in ATM (15%, 57%, 78% for general CLL population, CLL phase of RS, RS phase, respectively), TP53 (7%, 23%, 56%), NOTCH1 (6%, 23%, 50%), CDKN2A (<1%, 20%, 50%), SAMHD1 (2%, 13%, 33%), XPO1 (4%, 7%, 28%) and IRF4 (2%, 3%, 28%). IgHV analysis showed that all CLL/Richter samples were clonally related. The most frequently acquired mutations in the RS phase were TP53 and CDKN2A followed by SAMHD1, XPO1 and MED12. Central review of biopsy histology by two independent pathologists showed that 5 patients did not fulfill WHO diagnostic criteria of RS (Soilleux et al, Histopathology 2016) and were excluded from further analyses. However, mutation analysis of these biopsies revealed mutations associated with chemo-refractory CLL (3/5 TP53, 1/5 SAMHD1, 1/5 POT1) and clinical outcome of these patients was similar to patients with classical RS. Finally, we correlated the presence of mutations with progression-free (PFS) and overall (OS) survival (n=28). The median PFS was 5.8 months while OS after randomization was 11.5 months. None of the mutations alone was able to significantly stratify patient in terms of PFS and OS. Therefore, we combined the presence of high-risk mutations in any of the following 6 genes in the leukemic phase (NOTCH1, SF3B1, SAMHD1, DDX3X, FBXW7, KLHL6): patient with no mutation in these genes present a median PFS of 14.9 months compared to patients with at least one mutated gene who had a median PFS of 5.3 month (P=0.0022). Similar results were observed for OS (median OS >23.1 months vs 6.6 months, P=0.0242).

Conclusion: We show that CLL patients developing RS carry a high mutation burden and recurrent driver mutations in the leukemic clone and that additional mutations are acquired in the RS phase. We confirm the association of mutations in TP53, NOTCH1 and CDKN2A with RS and show in addition that SAMHD1 mutations are also frequently seen in RS. Finally, we propose that patients with biopsy findings of classical RS but no mutation in any of the 6 selected genes have an improved PFS and OS whereas patients without the classical RS biopsy features but a high-risk mutation profile fare poorly.

Disclosures

Eyre: GSK: Honoraria; Celgene: Other: Travel, Accomodation; Gilead: Honoraria, Other: Travel, Accomodation, Speakers Bureau; Takeda: Honoraria, Other: Travel, Speakers Bureau. Schuh:Gilead: Consultancy, Honoraria, Research Funding; Roche, Janssen, Novartis, Celgene, Abbvie: Consultancy, Honoraria.